Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT05279417
- Locations
- 🇵🇱
Aclaris Investigational Site, Wrocław, Poland
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 2
- Registration Number
- NCT05263505
- Locations
- 🇺🇸
Barnes Jewish Hospital / Washington University in St. Louis, Saint Louis, Missouri, United States
Medical Treatment in Ectopic Tubal Pregnancy
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Nishtar Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT05208034
- Locations
- 🇵🇰
Nishtar Medical University Hospital, Multān, Pu, Pakistan
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Conditions
- Interventions
- Drug: VenetoclaxDrug: NavitoclaxDrug: DexamethasoneDrug: VincristineDrug: Calaspargase PegolDrug: DasatinibDrug: LeucovorinDrug: CytarabineDrug: Intrathecal TriplesBiological: BlinatumomabDrug: PegaspargaseDrug: MethotrexateDrug: Erwinia asparaginaseDrug: MercaptopurineDrug: CyclophosphamideDrug: EtoposideRadiation: Radiation
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05192889
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05157971
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05137262
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT05102448
- Locations
- 🇨🇳
Lindi Jiang, Shanghai, Shanghai, China
Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL
- Conditions
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 488
- Registration Number
- NCT05054426
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, Beijing, China
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT05049473
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
🇪🇸ICO-Hospital Duran i Reynals, Bellvitge, Spain
Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 166
- Registration Number
- NCT05040464
- Locations
- 🇫🇷
CHU Amiens, Amiens, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.